AU2301700A - Human t cell effectors expressing cd86 molecule and therapeutic use thereof - Google Patents

Human t cell effectors expressing cd86 molecule and therapeutic use thereof

Info

Publication number
AU2301700A
AU2301700A AU23017/00A AU2301700A AU2301700A AU 2301700 A AU2301700 A AU 2301700A AU 23017/00 A AU23017/00 A AU 23017/00A AU 2301700 A AU2301700 A AU 2301700A AU 2301700 A AU2301700 A AU 2301700A
Authority
AU
Australia
Prior art keywords
molecule
human
therapeutic use
cell effectors
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23017/00A
Inventor
Jean-Yves Bonnefoy
Yves Delneste
Pascale Jeannin
Marc Vittori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2301700A publication Critical patent/AU2301700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU23017/00A 1999-02-02 2000-02-02 Human t cell effectors expressing cd86 molecule and therapeutic use thereof Abandoned AU2301700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9901187A FR2789089A1 (en) 1999-02-02 1999-02-02 HUMAN EFFECTOR T CELL LYMPHOCYTES EXPRESSING THE CD86 MOLECULE AND HAVING IMMUNODULATORY, COSTIMULATORY AND CYTOTOXIC PROPERTIES, METHODS OF OBTAINING THEM AND THEIR APPLICATIONS
FR9901187 1999-02-02
PCT/FR2000/000240 WO2000046352A1 (en) 1999-02-02 2000-02-02 Human t cell effectors expressing cd86 molecule and therapeutic use thereof

Publications (1)

Publication Number Publication Date
AU2301700A true AU2301700A (en) 2000-08-25

Family

ID=9541509

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23017/00A Abandoned AU2301700A (en) 1999-02-02 2000-02-02 Human t cell effectors expressing cd86 molecule and therapeutic use thereof

Country Status (6)

Country Link
EP (1) EP1149159A1 (en)
JP (1) JP2002535983A (en)
AU (1) AU2301700A (en)
CA (1) CA2360688A1 (en)
FR (1) FR2789089A1 (en)
WO (1) WO2000046352A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69731836T2 (en) * 1996-07-23 2005-12-01 Pangenetics B.V. INDUCTION OF T CELL TOLERANCE USING A SOLUBLE MOLECULAR THAT CAN CREATE TWO COSTIMULATION PATHS AT THE SAME TIME
AU5590198A (en) * 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Method of promoting b-cell proliferation and activation and of modulating the immune system

Also Published As

Publication number Publication date
WO2000046352A1 (en) 2000-08-10
EP1149159A1 (en) 2001-10-31
CA2360688A1 (en) 2000-08-10
JP2002535983A (en) 2002-10-29
FR2789089A1 (en) 2000-08-04

Similar Documents

Publication Publication Date Title
AU4860900A (en) Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
AU3957600A (en) Piperidyl-imidazole derivatives, their preparations and therapeutic uses
AU5129800A (en) Extracellular matrix and adhesion-associated proteins
AU6069300A (en) Novel human genes and gene expression products
AU2001273151A1 (en) Human extracellular matrix and cell adhesion polypeptides
AU2977700A (en) Personal physiological monitor
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2309700A (en) Oligonucleotide array and methods of use
AU2003221173A1 (en) Placenta-origin mesenchymal cells and medicinal use thereof
AU715620C (en) Therapeutic methods and uses
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU1164601A (en) Therapeutic use and formulation
AU5161399A (en) N-benzocycloalkyl-amide derivatives and their use as medicaments
AU5886500A (en) Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7748200A (en) Hypoxia-related human genes, proteins, and uses thereof
AU1608201A (en) Human zven proteins
AU2067501A (en) Human oxidoreductase proteins
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
AU1101901A (en) Human fgf-20 gene and gene expression products
AU3978700A (en) Medical use
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU3501700A (en) Human endokine alpha and methods of use
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU2001287269A1 (en) Human genes and expression products
AU1894601A (en) Novel gene and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase